कंपनी का अवलोकन
ANI Pharmaceuticals, Inc. operates as a biopharmaceutical entity dedicated to the development, manufacturing, and marketing of both branded and generic pharmaceutical products across the United States and international markets. The company functions within the Healthcare sector, specifically classified under the Drug Manufacturers - Specialty & Generic industry, which implies a focus on specialized therapeutic areas and cost-effective medication solutions for diverse patient populations. This organization employs approximately 970 individuals to support its operational footprint while maintaining a total market capitalization of $1.80 billion. Its annual revenue stands at $883.37 million, a valuation scale that positions the firm as a mid-sized player capable of sustaining significant R&D and manufacturing activities within the competitive pharmaceutical landscape. The substantial revenue generation relative to its market cap suggests a robust operational efficiency, while the employee count indicates a workforce size consistent with a company managing complex supply chains for injectables, softgel capsules, and specialized products like ILUVIEN and YUTIQ.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $883.37 million, generating a net income of $70.22 million and an EBITDA of $174.75 million during the same period. The significant disparity between the $883.37 million in revenue and the $70.22 million in net income reveals a cost structure where non-operating expenses, interest, taxes, or depreciation consume a considerable portion of top-line earnings before reaching the bottom line. ANI Pharmaceuticals demonstrated strong cash generation capabilities with free cash flow reaching $119.42 million, which provides the financial flexibility to fund operations, repay debt, or pursue strategic acquisitions without immediate reliance on external financing. The company maintains a gross margin of 61.4%, indicating high pricing power or efficient production costs relative to the sales price of its pharmaceutical goods. Furthermore, the operating margin sits at 12.0%, reflecting the efficiency of core business operations after covering variable costs, while the profit margin of 8.9% highlights the final profitability after all corporate expenses are deducted. In terms of liquidity and solvency, the firm holds $294.72 million in cash against $628.28 million in total debt, resulting in a debt-to-equity ratio of 116.19, which suggests a leveraged balance sheet typical for capital-intensive manufacturing sectors. Despite the leverage, the current ratio of 2.71 indicates a conservative stance on short-term liquidity, as the company holds more than double its current liabilities in liquid assets. Additionally, the return on equity is 16.2%, demonstrating effective management in generating profits from shareholder investments, whereas the return on assets is 3.8%, reflecting the capital intensity of the pharmaceutical manufacturing business.
मूल्यांकन आकलन
The valuation of ANI Pharmaceuticals is characterized by a trailing P/E ratio of 24.14 and a forward P/E of 7.62, a stark difference that implies the market expects a significant acceleration in future earnings growth relative to current performance levels. The price-to-book ratio is recorded at 3.11, indicating that the market values the company at a substantial premium over its net asset book value, likely due to intangible assets such as patents, brand equity, and proprietary formulations. Alternative valuation metrics further contextualize the stock's positioning, with a price-to-sales ratio of 2.04 and an EV/EBITDA of 11.48, suggesting the market is willing to pay a moderate multiple for its sales stream given its profitability profile. Regarding trading range, the stock has seen a 52-week high of $99.50 and a low of $56.71, meaning the current price sits significantly below the recent peak and near the lower end of its annual volatility band. The beta value of 0.43 indicates that the stock exhibits low price volatility relative to the broader market, moving less than half as much as the overall index during periods of market fluctuation.
Growth & Income
The company experienced a revenue growth of 29.6% year-over-year, while the earnings growth rate is listed as N/A, preventing a direct comparison of earnings velocity against sales expansion at this specific moment. Since earnings growth data is unavailable in the provided facts, the revenue expansion of 29.6% remains the primary indicator of top-line momentum without confirmation that profitability is scaling at the same pace. As a non-dividend payer, the company does not distribute a dividend yield or maintain a payout ratio, which signifies that the organization reinvests all net income into research, development, and manufacturing expansion rather than returning capital to shareholders. This growth-oriented capital allocation strategy aligns with the company's focus on developing new branded and generic products to sustain long-term revenue trajectories in the specialty and generic pharmaceutical sectors.